Table 2.
Correlation between p-Akt, E-cadherin, PCNA, and VEGF expression and clinicopathological features
| Variables | N | p-AKT+ n (%) | E-cad+ n (%) | Mean (SD) PCNA LI | VEGF+ n (%) |
| Age | |||||
| <60 | 42 | 14 (33.3%) | 19 (45.2%) | 56.5 (17.2) | 27 (64.3%) |
| ⩾60 | 42 | 15 (35.7%) | 21 (50.0%) | 57.5 (20.6) | 30 (71.4%) |
| Sex | |||||
| Male | 62 | 23 (37.1%) | 30 (48.4%) | 58.1 (19.3) | 41 (66.1%) |
| Female | 22 | 6 (27.3%) | 10 (45.5%) | 53.7 (17.3) | 16 (72.7%) |
| Smoking | |||||
| Yes | 40 | 15 (37.5%) | 15 (37.5%) | 58.1 (19.3) | 26 (65.0%) |
| No | 44 | 14 (31.8%) | 25 (56.8%) | 56.0 (18.5) | 31 (70.5%) |
| Alcohol | |||||
| <1 B/w | 39 | 12 (30.8%) | 20 (51.3%) | 57.4 (21.0) | 24 (61.5%) |
| ⩾1 B/w | 45 | 17 (37.8%) | 20 (44.4%) | 56.7 (17.0) | 33 (73.3%) |
| Differentiation | |||||
| Well | 61 | 19 (31.1%) | 32 (52.5%) | 56.0 (19.8) | 42 (68.9%) |
| Moderate/Poor | 23 | 10 (43.5%) | 8 (34.8%) | 59.7 (16.2) | 15 (65.2%) |
| Tumour size | |||||
| T1/T2 | 51 | 14 (27.5%) | 24 (47.1%) | 56.2 (17.1) | 36 (70.6%) |
| T3/T4 | 33 | 15 (45.5%) | 16 (48.5%) | 58.3 (21.4) | 21 (63.6%) |
| LN metastasis | |||||
| Positive | 29 | 15 (51.7%)* | 9 (31.0%)* | 58.2 (19.4) | 22 (75.9%) |
| Negative | 55 | 14 (25.5%)* | 31 (56.4%)* | 56.3 (18.6) | 35 (63.6%) |
| Clinical stage | |||||
| I/II | 42 | 9 (21.4%) * | 21 (45.2%) | 57.2 (17.4) | 28 (66.7%) |
| III/IV | 42 | 20 (47.6%)* | 19 (50.0%) | 56.8 (20.4) | 29 (69.0%) |
| Recurrence | |||||
| Yes | 29 | 13 (44.8%) | 10 (34.5%) | 53.9 (19.4) | 21 (72.4%) |
| No | 55 | 16 (29.1%) | 30 (54.5%) | 58.6 (18.5) | 36 (65.5%) |
*p<0.05, χ2 test.
1 B/w, 1 bottle (360 ml; 25% alcohol)/week; LN, lymph node; p-Akt, phosphorylated Akt; PCNA LI, proliferating cell nuclear antigen labelling index; VEGF, vascular endothelial growth factor.